Overview

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis.

Phase:

Phase 2

Details

Lead Sponsor:

Kiniksa Pharmaceuticals, Ltd.